Literature DB >> 3350907

Resistance to insulin-stimulated-glucose uptake in patients with hypertension.

D C Shen1, S M Shieh, M M Fuh, D A Wu, Y D Chen, G M Reaven.   

Abstract

Plasma glucose and insulin responses to a glucose challenge and insulin-stimulated glucose uptake were measured in 24 age-, weight-, and sex-matched Chinese men (8 with normal blood pressure, 8 with untreated hypertension, and 8 patients with hypertension treated with thiazide and beta-adrenergic antagonist drugs). Plasma glucose and insulin responses were determined by measuring plasma glucose and insulin concentrations before and at 30-min intervals for 2 h after a 75-g oral glucose dose. Insulin-stimulated glucose uptake was estimated by measuring the steady state plasma glucose (SSPG) and insulin (SSPI) concentrations achieved during the last 60 min of a 180-min continuous infusion of somatostatin, insulin, and glucose (insulin suppression test). Under these conditions endogenous insulin secretion was suppressed, and similar SSPI concentrations were achieved in all men; thus, the differences in the resultant SSPG concentrations allowed direct comparison of insulin's ability to stimulate disposal of an identical glucose load in different individuals. The results indicated that the men with hypertension, whether treated or untreated, had significantly elevated plasma glucose (P less than 0.001) and insulin (P less than 0.001) responses to the oral glucose dose compared to the normal men. Mean (+/- SE) SSPG concentrations were also higher (P less than 0.001) in the men with either untreated hypertension [219 +/- 9 mg/dL (12.2 +/- 0.5 mmol/L)] or treated hypertension [211 +/- 18 mg/dL (11.7 +/- 1.0 mmol/L)] than in the normal men [134 +/- 13 mg/dL (7.4 +/- 0.7 mmol/L)]. Since the mean SSPI concentrations were similar in the 3 groups [approximately 70 microU/mL (502 pmol/L)], insulin was less effective in promoting glucose disposal in both groups with hypertension. These results document the fact that patients with hypertension, whether treated or untreated, are insulin resistant, hyperglycemic, and hyperinsulinemic compared to a well-matched control group.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3350907     DOI: 10.1210/jcem-66-3-580

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  45 in total

1.  Potassium and magnesium in essential hypertension.

Authors:  P S Patki; G S Gokhale; J Singh; D S Shrotri; B Patwardhan
Journal:  BMJ       Date:  1990-12-01

2.  Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.

Authors:  E A Anderson; R P Hoffman; T W Balon; C A Sinkey; A L Mark
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 3.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

4.  Plasma adiponectin and insulin resistance in new onset hypertension.

Authors:  Teoman Dogru; Alper Sonmez; Ilker Tasci; M Ilker Yilmaz; Selim Kilic; Taner Ozgurtas; Tayfun Eyileten; M Kemal Erbil; I Hakki Kocar
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

Review 5.  Insulin resistance and hypertension.

Authors:  M Lachaal; C Y Jung
Journal:  Mol Cell Biochem       Date:  1992-02-12       Impact factor: 3.396

Review 6.  Insulin resistance and hypertension--implications for treatment.

Authors:  P A Rutherford; T H Thomas; R Wilkinson
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

Review 7.  The chronic cardiovascular risk factor syndrome (syndrome X): mechanisms and implications for atherogenesis.

Authors:  S C Bain; P M Dodson
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

8.  Hypertension and non-insulin dependent diabetes.

Authors:  J S Yudkin
Journal:  BMJ       Date:  1991-09-28

9.  Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.

Authors:  T A Buchanan; W P Meehan; Y Y Jeng; D Yang; T M Chan; J L Nadler; S Scott; R K Rude; W A Hsueh
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 10.  Hypertension management in patients with diabetic nephropathy.

Authors:  Anthony L McCall
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.